Literature DB >> 16269018

Erythrocyte transport efficacy of human blood: a rheological point of view.

L Bogar1, I Juricskay, G Kesmarky, P Kenyeres, K Toth.   

Abstract

BACKGROUND: Large-scale epidemiological studies have demonstrated that both anaemia and polycytaemia are independent cardiovascular risk factors. This was substantiated by the Framingham study, which demonstrated a U-shaped relation between haemoglobin concentration and mortality. It was previously noted that delineating the corresponding haematocrit/blood viscosity ratios in the function of haematocrit provided a distribution of an inverted U-shaped curve. The peak appeared physiologically important because it denotes a healthy balance between a relatively high oxygen binding capacity and a moderately low blood viscosity. It was the aim of this study to examine the mathematical relationship between the haematocrit and haematocrit/blood viscosity ratio.
MATERIALS AND METHODS: In a retrospective study, the haemorheological data of 32 healthy controls, 52 outpatients with hyperlipidaemia and 120 outpatients with Raynaud's disease were analyzed. Whole blood viscosity was measured with Hevimet 40 capillary viscometer at 37.0 degrees C and at shear rates of 10 s(-1), 90 s(-1) and 200 s(-1).
RESULTS: Haematocrit/blood viscosity ratios in the function of haematocrit values showed a Gaussian association in the healthy subjects, hyperlipidaemic and Raynaud's disease outpatient groups. Peak values (i.e. the rheologically optimal haematocrit) were shear-rate and group dependent and were found at 44.3%, 43.5% and 38.3% in controls, hyperlipidaemic and Raynaud's disease patients, respectively, at a shear rate of 90 s(-1).
CONCLUSIONS: This is one of the first reports in which a theoretically optimal haematocrit value was determined using the haematocrit/blood viscosity ratio. Further studies are needed to examine the potential clinical usefulness of this approach.

Entities:  

Mesh:

Year:  2005        PMID: 16269018     DOI: 10.1111/j.1365-2362.2005.01562.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Optimal hematocrit in an artificial microvascular network.

Authors:  Nathaniel Z Piety; Walter H Reinhart; Julianne Stutz; Sergey S Shevkoplyas
Journal:  Transfusion       Date:  2017-07-05       Impact factor: 3.157

2.  The role of hemorheological factors in cardiovascular medicine.

Authors:  A Toth; J Papp; M Rabai; P Kenyeres; Zs Marton; G Kesmarky; I Juricskay; H J Meiselman; K Toth
Journal:  Clin Hemorheol Microcirc       Date:  2014       Impact factor: 2.375

3.  Low-shear red blood cell oxygen transport effectiveness is adversely affected by transfusion and further worsened by deoxygenation in sickle cell disease patients on chronic transfusion therapy.

Authors:  Jon Detterich; Tamas Alexy; Miklos Rabai; Rosalinda Wenby; Ani Dongelyan; Thomas Coates; John Wood; Herbert Meiselman
Journal:  Transfusion       Date:  2012-08-06       Impact factor: 3.157

4.  Red blood cell aggregation, aggregate strength and oxygen transport potential of blood are abnormal in both homozygous sickle cell anemia and sickle-hemoglobin C disease.

Authors:  Julien Tripette; Tamas Alexy; Marie-Dominique Hardy-Dessources; Daniele Mougenel; Eric Beltan; Tawfik Chalabi; Roger Chout; Maryse Etienne-Julan; Olivier Hue; Herbert J Meiselman; Philippe Connes
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

5.  Exercise-induced blood lactate increase does not change red blood cell deformability in cyclists.

Authors:  Michael J Simmonds; Philippe Connes; Surendran Sabapathy
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

6.  Blood viscosity and the expression of inflammatory and adhesion markers in homozygous sickle cell disease subjects with chronic leg ulcers.

Authors:  Andre S Bowers; Harvey L Reid; Andre Greenidge; Clive Landis; Marvin Reid
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.